Author
Listed:
- Georgia Hatzivassiliou
(Genentech, South San Francisco, California 94080, USA)
- Kyung Song
(Genentech, South San Francisco, California 94080, USA)
- Ivana Yen
(Genentech, South San Francisco, California 94080, USA)
- Barbara J. Brandhuber
(Array BioPharma, Boulder, Colorado 80301, USA)
- Daniel J. Anderson
(Genentech, South San Francisco, California 94080, USA)
- Ryan Alvarado
(Genentech, South San Francisco, California 94080, USA)
- Mary J. C. Ludlam
(Genentech, South San Francisco, California 94080, USA)
- David Stokoe
(Genentech, South San Francisco, California 94080, USA)
- Susan L. Gloor
(Array BioPharma, Boulder, Colorado 80301, USA)
- Guy Vigers
(Array BioPharma, Boulder, Colorado 80301, USA)
- Tony Morales
(Array BioPharma, Boulder, Colorado 80301, USA)
- Ignacio Aliagas
(Genentech, South San Francisco, California 94080, USA)
- Bonnie Liu
(Genentech, South San Francisco, California 94080, USA)
- Steve Sideris
(Genentech, South San Francisco, California 94080, USA)
- Klaus P. Hoeflich
(Genentech, South San Francisco, California 94080, USA)
- Bijay S. Jaiswal
(Genentech, South San Francisco, California 94080, USA)
- Somasekar Seshagiri
(Genentech, South San Francisco, California 94080, USA)
- Hartmut Koeppen
(Genentech, South San Francisco, California 94080, USA)
- Marcia Belvin
(Genentech, South San Francisco, California 94080, USA)
- Lori S. Friedman
(Genentech, South San Francisco, California 94080, USA)
- Shiva Malek
(Genentech, South San Francisco, California 94080, USA)
Abstract
Mixed signals from RAF Abnormal activation of the RAS-RAF-MEK-ERK signalling pathway is a feature of many human cancers, making it an attractive target for antitumour therapy. Several RAF and MEK inhibitors are in clinical trials, but an unexpected complication has emerged. Although selective BRAF inhibitors are effective in treating mutant BRAF melanoma, in which they potently suppress RAF-MEK-ERK signalling, the same inhibitors are ineffective against tumours that carry an oncogenic mutation in the KRAS gene. Two groups now report that the reason for this dramatic difference is that RAF 'inhibitors' have dual activity, functioning as either inhibitors or activators of RAF, depending on the cellular context and mutational status of RAF. In News & Views, Karen Cichowski and Pasi Jänne discuss the mechanistic and clinical implications of these findings and similar work reported in Cell.
Suggested Citation
Georgia Hatzivassiliou & Kyung Song & Ivana Yen & Barbara J. Brandhuber & Daniel J. Anderson & Ryan Alvarado & Mary J. C. Ludlam & David Stokoe & Susan L. Gloor & Guy Vigers & Tony Morales & Ignacio A, 2010.
"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,"
Nature, Nature, vol. 464(7287), pages 431-435, March.
Handle:
RePEc:nat:nature:v:464:y:2010:i:7287:d:10.1038_nature08833
DOI: 10.1038/nature08833
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Revati Darp & Marc A. Vittoria & Neil J. Ganem & Craig J. Ceol, 2022.
"Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis,"
Nature Communications, Nature, vol. 13(1), pages 1-17, December.
- Maria Szaruga & Dino A. Janssen & Claudia Miguel & George Hodgson & Agnieszka Fatalska & Aleksandra P. Pitera & Antonina Andreeva & Anne Bertolotti, 2023.
"Activation of the integrated stress response by inhibitors of its kinases,"
Nature Communications, Nature, vol. 14(1), pages 1-15, December.
- Peter Rashkov & Ian P Barrett & Robert E Beardmore & Claus Bendtsen & Ivana Gudelj, 2016.
"Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle,"
PLOS Computational Biology, Public Library of Science, vol. 12(11), pages 1-15, November.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:464:y:2010:i:7287:d:10.1038_nature08833. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.